Sarepta Therapeutics Inc (SRPT)
Liquidity ratios
| Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current ratio | 4.05 | 3.95 | 5.44 | 4.96 | 4.63 | 4.13 | 4.36 | 4.53 | 5.56 | 5.75 | 5.85 | 5.33 | 6.23 | 5.97 | 6.14 | 6.93 | 8.31 | 5.55 | 6.31 | 8.81 |
| Quick ratio | 2.91 | 3.18 | 4.55 | 4.21 | 3.92 | 3.56 | 3.77 | 3.91 | 4.82 | 5.01 | 4.68 | 4.36 | 5.09 | 4.90 | 5.12 | 6.10 | 7.43 | 4.59 | 5.17 | 7.16 |
| Cash ratio | 2.28 | 2.56 | 3.85 | 3.73 | 3.51 | 3.21 | 3.44 | 3.53 | 4.43 | 4.67 | 4.28 | 4.06 | 4.76 | 4.66 | 4.80 | 5.81 | 7.09 | 4.25 | 4.86 | 6.81 |
Sarepta Therapeutics Inc has displayed consistently strong liquidity ratios over the past few quarters. The current ratio has remained above 4, indicating that the company has more than enough current assets to cover its current liabilities, providing a comfortable buffer for short-term obligations. The increasing trend in the current ratio from 2020 to 2024 suggests an improvement in the company's ability to meet its short-term financial obligations.
The quick ratio, which excludes inventory from current assets, also reflects a healthy liquidity position for Sarepta Therapeutics Inc. It has consistently stayed above 3, indicating that the company can meet its short-term liabilities using only its most liquid assets. This reflects a prudent approach to managing liquidity and mitigating potential short-term risks.
Furthermore, the cash ratio has demonstrated a similar trend of improvement, remaining above 2 in most quarters. This ratio shows the extent to which the company's cash and cash equivalents can cover its current liabilities, providing a more conservative measure of liquidity. The increasing cash ratio over time suggests that Sarepta Therapeutics Inc has been building up its cash reserves, further enhancing its ability to meet immediate financial obligations.
Overall, the liquidity ratios of Sarepta Therapeutics Inc indicate a strong financial position with ample liquidity to support its short-term operational needs and weather any unforeseen financial challenges.
Additional liquidity measure
| Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash conversion cycle | days | 292.68 | 230.60 | 218.87 | 179.48 | 154.70 | 172.03 | 175.48 | 238.70 | 268.32 | 218.36 | 386.10 | 306.99 | 269.91 | 206.99 | 259.08 | 186.61 | 269.53 | 219.07 | 182.77 | 227.25 |
The cash conversion cycle of Sarepta Therapeutics Inc has shown some fluctuation over the periods analyzed.
The company's cash conversion cycle, which represents the time it takes for a company to convert its investments in inventory and other resources into cash flows from sales, has ranged from 154.70 days to 386.10 days over the past few quarters.
It appears that in some periods, such as Dec 31, 2021, and Jun 30, 2021, the company had a longer cash conversion cycle, indicating that it took longer for the company to turn its investments in inventory and other resources into cash compared to other periods. This could suggest potential inefficiencies in managing its working capital or inventory levels during those quarters.
Conversely, in periods like Mar 31, 2023, and Dec 31, 2020, the company had a shorter cash conversion cycle, implying that it was more efficient in converting investments into cash during those quarters.
Overall, monitoring the cash conversion cycle can provide insights into how effectively Sarepta Therapeutics Inc manages its working capital and the efficiency of its operations in generating cash flows from its sales and investments.